IMMUNOTHERAPY FOR LOCALLY ADVANCED AND METASTATIC MALIGNANT MELANOMA

Ciprian Enachescu, Sena Yossi, Mouna Darfaoui, Tristan Brahmi, Victor Gabriel Clatici, Ionela Caraivan, Alina Tita, Corina Girleanu

Abstract


Metastatic malignant melanoma is a potentially fatal cancer with a survival rate between 10% to 20% at 5-years and a poor prognosis that can be in part due to limited efficacy of standard chemotherapy regimens. To improve these results different immunological interventions, including cytokine based therapies, anti-tumour vaccination and checkpoint inhibition, have been developed, in order to stimulate the proliferation and activation of T lymphocytes to destroy tumor cells. In this review we summarize the main immunotherapy approaches against metastatic melanoma. 

Key words: metastatic melanoma, immunotherapy, cytokine therapies, anti-tumour vaccination, checkpoint inhibitors, Ipilimumab, Nivolumab, Pembrolizumab.

Ciprian Enachescu, Sena Yossi, Mouna Darfaoui, Tristan Brahmi, Victor Gabriel Clatici, Ionela Caraivan, Alina Tita, Corina Girleanu. Immunotherapy for locally advanced and metastatic malignant melanoma. RoJCED 2017;3(4):156-164.

https://doi.org/10.26574/rojced.2017.4.3.156 

 

 


Full Text:

PDF

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 Romanian Journal of Clinical and Experimental Dermatology

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

—Print : ISSN 2392–7461, ISSN-L 2392–7461 
—Online : ISSN 2392-8697, ISSN-L 2392-7461

Editor-In-Chief and Managing Editor - Victor Gabriel Clatici
 

 

 

Creative Commons License
Romanian Journal of Clinical and Experimental Dermatology by Tarus Media is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Based on a work at http://www.rojced.com/index.php/rojced/index.
Permissions beyond the scope of this license may be available at tarusmedia.ro